Journal of Diabetes and Its Complications
Volume 18, Issue 3 , Pages 183-186 , May 2004

Different effects of two α-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level

Received 30 November 2002 ,Revised 6 April 2003 ,Accepted 11 April 2003.

References 

  1. Ahr HJ, Boberg M, Krause HP, Maul W, Muller FO, Ploschke HJ, et al. Pharmacokinetics of acarbose: Part I. Absorption, concentration in plasma, metabolism and excretion after single administration of [14C] acarbose to rats, dogs and man. Arzneimittel-Forschung. 1989;39:1254–1260
  2. Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H. Urinary excretion of 1,5-anhydro-d-glucitol accompanying glucose excretion in diabetic patients. Diabetologia. 1988;31:831–835
  3. Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Archives of Internal Medicine. 1994;154:2442–2448
  4. Hillebrand I, Boehme K, Frank G, Fink H, Berchtold P. The effects of the α-glucosidase inhibitor BAY g 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man. Research in Experimental Medicine (Berlin). 1979;175:81–86
  5. Hotta N, Koh N, Sakakibara F, Naruse F, Yamada K, Takeuchi T, et al. Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-d-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy. Biomedicine & Pharmacotherapy. 1996;50:297–302
  6. Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care. 1998;21:2056–2061
  7. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawa-mori R, et al. 1,5-Anhydro-d-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care. 1995;18:1156–1159
  8. Leonhardt W, Hanefeld M, Fischer S, Schulze J. Efficacy of α-glucosidase inhibitors on lipid in NIDDM subjects hyperlipidaemia. European Journal of Clinical Investigation. 1994;24:45–49 Suppl
  9. Matsumoto I, Kuhara T. A new chemical diagnostic method for inborn errors of metabolism by mass spectrometry—rapid, practical, and simultaneous urinary metabolites analysis. Mass Spectrometry Reviews. 1996;15:43–57
  10. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 1998;21:256–260
  11. Sakane N, Yoshida T, Kogure A, Kondo M. Different effects of acarbose and voglibose on serum 1,5-anhydroglucitol concentrations (letter). Diabetes Care. 1998;21:465–466
  12. Servo C, Pitkanen E. Variation in polyol levels in cerebrospinal fluid and serum in diabetic patients. Diabetologia. 1975;11:575–580
  13. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism. 1996;45:731–737
  14. Shoemaker JD, Elliot WH. Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. Journal of Chromatography. 1991;562:125–138
  15. Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5AG): new clinical marker for glycemic control. Diabetes Research and Clinical Practice. 1994;24:S261–S268 Supplement
  16. Yamanouchi T, Minoda S, Yabuuchi M, Yabuuchi M, Akanuma Y, Akanuma H, et al. Plasma 1,5-anhydro-d-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes. 1989;38:723–729
  17. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996;347:1514–1518
  18. Yamanouchi T, Tachibana Y, Akanuma H, Minoda S, Shinohara T, Moromizato H, et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. American Journal of Physiology. 1992;263:E268–E273
  19. Yoshioka K, Azukari K, Yoshida T, Kondo M. Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of α-glucosidase inhibitor (letter). Diabetes Care. 1997;20:462

PII: S1056-8727(03)00055-2

doi: 10.1016/S1056-8727(03)00055-2

Journal of Diabetes and Its Complications
Volume 18, Issue 3 , Pages 183-186 , May 2004

Article Tools